Bayer BAYRY announced a licensing agreement with Suzhou Puhe BioPharma Co., a clinical-stage biotechnology company.Suzhou Puhe BioPharma is focused on the research and development of innovative ...

We, like so many others, have been forced to take steps to extend our cash runway,” said Tango’s CEO, citing “extremely ...

Under the agreement, Bayer obtains an exclusive worldwide license to develop, manufacture and commercialize the MTA-cooperative PRMT5 inhibitor. Bayer has enrolled the first participant in a Phase ...

Per the deal terms, Bayer (OTCPK:BAYRY) will receive an exclusive worldwide license from Puhe to develop, manufacture, and commercialize Puhe's drug candidate identified as MTA-cooperative PRMT5 ...

Top of the list is PRMT5/MTA inhibitor MRTX1719, which BMS said could be a first-in-class therapy for cancers with MTAP deletions seen in around 10% of all cancers, including NSCLC, as well as ...

The companies have collaborated for Suzhou Puhe BioPharma’s oral, small molecule protein arginine N-methyltransferase 5 (PRMT5) inhibitor that selectively targets methylthioadenosine ...